Replies to post #5788 on Halozyme Therapeutics Inc (HALO)

[maumar]

Economic Moat

Anna Baran, Eq. Analyst, 03 December 2019

Now that Darzalex (daratumumab) has become clearly entrenched in the standard of care for multiple myeloma (MM)patients, we are upgrading Genmab's moat from none to narrow. We think it is highly unlikely that Darzalex gets dethroned from its dominant market position in the next 10 years.